Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

IntroductionThe combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). However, the response of the tumor microenvironment to FOLFOX-Bev is still largely unexplored.MethodsWe conducted single-cell transcriptomic analysis of CRC samples deriv...

Full description

Bibliographic Details
Main Authors:	Meiling Yang, Ciqiu Yang, Dong Ma, Zijun Li, Wei Zhao, Dongyang Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Oncology
Subjects:	advanced colorectal cancer single-cell transcriptomic analysis FOLFOX bevacizumab VEGF
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1219642/full

Similar Items

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018-05-01)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
by: Erin D. Powell, et al.
Published: (2009-07-01)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
by: Yujing Xin, et al.
Published: (2022-08-01)

Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
by: Lyu Ning, et al.
Published: (2022-01-01)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
by: Taku Naiki, et al.
Published: (2017-11-01)

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature
by: Sho Watanabe, et al.
Published: (2017-05-01)

Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats
by: Juste Maneikyte, et al.
Published: (2020-08-01)

Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3Research in context
by: Guifang Li, et al.
Published: (2024-04-01)

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells
by: Shing-Yau Tam, et al.
Published: (2023-06-01)

Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report
by: Minna Kim, et al.
Published: (2023-12-01)

Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
by: Shyam Aggarwal
Published: (2015-11-01)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
by: Kohei Shitara, et al.
Published: (2010-07-01)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
by: Wei Lu, et al.
Published: (2020-02-01)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
by: Xiaoying Hou, et al.
Published: (2021-09-01)

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
by: Alessandro Ottaiano, et al.
Published: (2021-09-01)

Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy
by: Rahmawati Minhajat, et al.
Published: (2021-05-01)

Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
by: Liu X, et al.
Published: (2021-01-01)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
by: Yiyi Zhang, et al.
Published: (2021-01-01)

The Effect of Intravitreal Bevacizumab on Apoptosis of Rat Retina Cells
by: Özcan Kayıkçıoğlu, et al.
Published: (2013-01-01)

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
by: Shukui Qin, et al.
Published: (2018-08-01)

Global impact of KRAS mutations patterns in FOLFOX treated metastatic colorectal cancer
by: David eMolinas Zocche, et al.
Published: (2015-03-01)

Protective effect of miR‐18a in resected liver metastases of colorectal cancer and FOLFOX treatment
by: Clemens Franz, et al.
Published: (2023-12-01)

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment
by: Zhou Y, et al.
Published: (2023-06-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

Retrospective Analysis of the Safety of FOLFOX Compared to CAPOX for Adjuvant Treatment of Stage III Colorectal Cancer in Newfoundland Patients
by: Joshua N. McShane, et al.
Published: (2022-09-01)

The role of bevacizumab in the treatment of patients with ovarian and cervical cancer
by: S V Khokhlova
Published: (2017-01-01)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
by: Ioana Mihaela Dinu, et al.
Published: (2023-02-01)

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
by: Mehdi Dehghani, et al.
Published: (2015-07-01)

Use of Bevacizumab in the Treatment of Corneal Neovascularization
by: Tuba Çelik, et al.
Published: (2015-01-01)

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia
by: Dhouha Jamai, et al.
Published: (2023-07-01)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
by: Keisuke Okuno, et al.
Published: (2023-01-01)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
by: Antonia Martinetti, et al.
Published: (2014-08-01)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
by: Takao Takahashi, et al.
Published: (2022-09-01)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
by: Jii Bum Lee, et al.
Published: (2020-04-01)

Bevacizumab intravítreo como tratamiento de maculopatías miópicas neovasculares
by: Dana Martinez M, et al.
Published: (2017-07-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
by: Amy eBarone, et al.
Published: (2013-04-01)

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada – a time and motion study
by: Shinder Gayle A, et al.
Published: (2012-10-01)

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report
by: Clizia Zichi, et al.
Published: (2018-04-01)